Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vanta Bioscience's Enterprise Value is ₹559.29 Mil.
Vanta Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6.32 Mil. Therefore, Vanta Bioscience's EV-to-EBIT ratio for today is 88.57.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Vanta Bioscience's Enterprise Value is ₹559.29 Mil.
Vanta Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹12.46 Mil. Therefore, Vanta Bioscience's EV-to-EBITDA ratio for today is 44.87.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Vanta Bioscience's Enterprise Value is ₹559.29 Mil.
Vanta Bioscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹18.16 Mil. Therefore, Vanta Bioscience's EV-to-Revenue ratio for today is 30.79.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Vanta Bioscience's Enterprise Value is ₹559.29 Mil.
Vanta Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-52.19 Mil. Therefore, Vanta Bioscience's EV-to-FCF ratio for today is -10.72.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Vanta Bioscience (BOM:540729) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Vanta Bioscience's current Enterprise Value is ₹559.29 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vanta Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6.32 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Vanta Bioscience's current Enterprise Value is ₹559.29 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vanta Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹12.46 Mil.
Vanta Bioscience's current Enterprise Value is ₹559.29 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vanta Bioscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹18.16 Mil.
Vanta Bioscience's current Enterprise Value is ₹559.29 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vanta Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-52.19 Mil.
Vanta Bioscience's current Enterprise Value is ₹559.29 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Vanta Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-52.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience Enterprise Value Related Terms
Vanta Bioscience Enterprise Value Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540729 vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Vanta Bioscience's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience (BOM:540729) has a Enterprise Value of ₹559.29 Mil as of Jul. 21, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vanta Bioscience and its competitors.
Is Vanta Bioscience's Enterprise Value too high?
Vanta Bioscience's current Enterprise Value is ₹559.29 Mil. Overall, Vanta Bioscience has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Enterprise Value compare to TMO and DHR?
Vanta Bioscience's Enterprise Value of ₹559.29 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vanta Bioscience and its competitors. Vanta Bioscience's current Enterprise Value is ₹559.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.97, compared to a current price of ₹25.29 — trading 111.3% above its estimated fair value. The current Enterprise Value is ₹559.29 Mil. Vanta Bioscience's overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Enterprise Value is ₹559.29 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹25.29 is trading 111.3% above its estimated GF Value™ of ₹11.97.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
Enterprise Value: ₹559.29 Mil
GF Value™: ₹11.97 vs. price of ₹25.29 (111.3% above fair value)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
50GF Score
Get the complete analysis for BOM:540729
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
